Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Schwartz

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Haematologica|October 15, 2020
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programsDebora Soncini, Stefania Orecchioni, Samantha Ruberti, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Clinical Psychology in Europe|December 16, 2024
Developing a European Psychotherapy Consortium (EPoC): Towards Adopting a Single-Item Self-Report Outcome Measure Across European CountriesMiguel M Gonçalves, Wolfgang Lutz, Brian Schwartz, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Psychotherapy Research : Journal of the Society for Psychotherapy Research|June 4, 2024
Love yourself as a therapist, doubt yourself as an institution? Therapist and institution effects on outcome, treatment length, and dropoutAnne-Katharina Deisenhofer, Miriam I Hehlmann, Julian A Rubel, et al.
The Lancet. Oncology|November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
JACC. Cardiovascular Interventions|March 15, 2023
Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights From the Optimize PRO StudyKendra J Grubb, Hemal Gada, Suneet Mittal, et al.
Behaviour Research and Therapy|February 7, 2025
Effectiveness of cognitive behavioral therapy for adult mental disorders: A large-scale naturalistic study across 29 university outpatient clinicsJulia Velten, Hanna Christiansen, Jürgen Hoyer, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Haematologica|October 15, 2020
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programsDebora Soncini, Stefania Orecchioni, Samantha Ruberti, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancerDavid E Gerber, Mark A Socinski, Joel W Neal, et al.
Clinical Psychology in Europe|December 16, 2024
Developing a European Psychotherapy Consortium (EPoC): Towards Adopting a Single-Item Self-Report Outcome Measure Across European CountriesMiguel M Gonçalves, Wolfgang Lutz, Brian Schwartz, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Psychotherapy Research : Journal of the Society for Psychotherapy Research|June 4, 2024
Love yourself as a therapist, doubt yourself as an institution? Therapist and institution effects on outcome, treatment length, and dropoutAnne-Katharina Deisenhofer, Miriam I Hehlmann, Julian A Rubel, et al.
The Lancet. Oncology|November 28, 2012
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Lorenza Rimassa, Ivan Borbath, et al.
JACC. Cardiovascular Interventions|March 15, 2023
Clinical Impact of Standardized TAVR Technique and Care Pathway: Insights From the Optimize PRO StudyKendra J Grubb, Hemal Gada, Suneet Mittal, et al.
Behaviour Research and Therapy|February 7, 2025
Effectiveness of cognitive behavioral therapy for adult mental disorders: A large-scale naturalistic study across 29 university outpatient clinicsJulia Velten, Hanna Christiansen, Jürgen Hoyer, et al.
Pageof 21